Andrin oswald biography of rory

Home / Celebrity Biographies / Andrin oswald biography of rory

- 11:00 a.m. Treat.

Founded in 2006, CENTOGENE has long been known for its expertise in the field of rare disease genetics – helping over 600,000 patients and building a rare disease-centric Bio/Databank. I have known and followed CENTOGENE for many years and am deeply impressed by CENTOGENE’s potential for value creation as we execute on the next chapter of our strategy.”

Peer Schatz, Chairman of the Supervisory Board of CENTOGENE said, “We are very much looking forward to developing and executing on our opportunities with Kim Stratton as our Chief Executive Officer.

Kim Stratton’s appointment as a managing director will be formalized at the next shareholder meeting.

Kim Stratton has more than 25 years’ global commercial expertise in the biopharmaceutical space, with significant experience across multiple geographies, including the U.K., U.S., Europe, and emerging markets.

This represents the potential to significantly contribute to reducing the burden of rare diseases.”

“This next chapter is powered by our unparalleled genomics knowledge, the world’s largest rare disease-centric Bio/Databank, global footprint, and strong established network of physicians, partners, and patients. Oswald is an accomplished leader in healthcare with a strong track record of building global companies focused on purpose, innovation and excellence,” said Dr.

Flemming Ørnskov, Chairman of CENTOGENE’s Supervisory Board. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository of over 600,000 patients representing over 120 different countries.

The Company’s platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, as well as a biobank of patients’ blood samples and cell cultures.

Examples include discussion of our strategies, financing plans, growth opportunities, and market growth. - 5:00 p.m. “With Prof. “CENTOGENE has a clear mission and a committed and excellent team that will help drive a very exciting future for the Company. While Dr. Oswald is on a path to recovery, this will take some additional time, and Dr.

Oswald has therefore decided, in consultation and mutual agreement with the Company’s supervisory board, to hand over the CEO position to Kim Stratton to ensure continued strong leadership. He pursued a Doctor of Medicine (MD) degree at the prestigious University of Geneva, equipping him with comprehensive medical knowledge and clinical insights.

Leveraging its rare disease expertise while expanding technology capabilities, CENTOGENE is confident about its path to enabling the cure of 100 rare diseases.

Register for the VirtualInvestorEvent

The Company will be hosting the Virtual Investor Event today, June 22, 2021, at 9:00 a.m. As of August 31, 2020, the Company collaborated with over 40 pharmaceutical partners covering over 45 different rare diseases.

Important Notice and Disclaimer

This press release contains statements that constitute “forward looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts.

CENTOGENE believes this represents the only platform focused on comprehensive analysis of multi-level data to improve the understanding of rare hereditary diseases. We are now embarking on our next growth phase – enabling the cure of 100 rare diseases within the next 10 years. Rolfs’ leadership, CENTOGENE has evolved from its inception in 2006 into what is now the world’s leading partner and knowledge resource for diagnosis and research around rare diseases.

He has been at the forefront of developing innovative approaches to vaccine distribution, regulatory engagement, and stakeholder collaboration, which have resulted in significant advancements in public health. Before Shire, Mrs. Stratton spent nearly 15 years at Novartis in a number of senior management roles, including global product development, commercial, marketing, general manager, and various global corporate functions, including government and external affairs.

As a member of the Novartis Executive Committee, he played a critical role in steering the company towards impactful healthcare solutions.

and ROSTOCK, Germany and BERLIN, June 22, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, will hold its first Virtual Investor Event, presented by its newly formed executive team.

Andrin Oswald, M.D., Chief Executive Officer at CENTOGENE, stated, “Over the past 15 years, CENTOGENE has built a unique expertise and has become the leading data-driven insights provider purely focused on rare genetic diseases.

“CENTOGENE is at a very important time in its development that requires continued strong leadership.